Glenmark Pharmaceuticals, a global pharmaceutical company, today announced data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID) in Orlando, Florida.

The exploratory Phase 2a study was conducted to investigate the safety of GBR 830, evaluate its effects on AD biomarkers, and generate the first clinical evidence of its biological activity. Patients were randomized to receive two doses of GBR 830 or placebo, and were assessed for response at Day 29 and Day 71.

New data from the study demonstrated that subsequent to treatment with GBR 830, epidermal hyperplasia, proliferation, and mRNA biomarkers for disease activity were reduced, indicating a possible effect on both the acute and chronic stages of AD.

''This biomarker evidence further validates our recently announced decision to rapidly advance the clinical development of GBR 830,'' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. ''At Glenmark, we are committed to the pursuit of this potential new treatment for atopic dermatitis, and this biomarker data may provide important information for future clinical decision making.''

Shares of the company declined Rs 1.15, or 0.22%, to trade at Rs 516.90. The total volume of shares traded was 4,215 at the BSE (9.59 a.m., Friday).